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Increased expression of TGF-1 and IGF-I in inflammatory quiring surgical revision [1–3]. The primary arteriove-
stenotic lesions of hemodialysis fistulas. nous (AV) fistula is widely accepted as the best perma-
Background. Hemodialysis fistula dysfunction due to ste- nent vascular access in hemodialysis patients [1, 3, 4].notic lesions remains a frequent cause of hospitalization for
Early fistula failure is usually ascribed to thrombosis,hemodialysis patients. Transforming growth factor- (TGF-)
and insulin-like growth factor-I (IGF-I) are known to be in- which can be triggered by hematoma or seroma, low
volved in atherogenesis. The latent TGF-1 binding protein-1 flow rates resulting from low blood pressure, or by a
(LTBP-1) targets extracellular matrix (ECM) interactions and hypercoagulable state [1–4]. In contrast, late thrombosis
is involved in the regulation of TGF- latency.
of a hemodialysis fistula is related to stenotic lesions inMethods. We investigated the expression of TGF-1, LTBP-1
the venous outflow system [2–5]. These lesions oftenand IGF-I in 15 occluded or severely narrowed vein segments
of primary arteriovenous fistulas, in 29 non-stenosed control develop on the basis of progressive neointimal hyperpla-
veins from uremic, pre-dialysis patients, and in 15 non-stenosed sia [5] the pathogenesis of which is not fully understood.
control saphenous veins obtained from patients undergoing Since locally acting growth factors, including transform-aortocoronary bypass grafting. Immunohistochemistry was per-
ing growth factor-1 (TGF-1) and insulin-like growthformed on snap-frozen tissue specimens using antibodies recog-
nizing either the latency-associated peptide of TGF-1 (96-1), factor-I (IGF-I) [6, 7], are involved in the initiation and
LTBP-1 (Ab39) or IGF-I. Serum levels of TGF-1 and IGF-I progression of atherosclerotic plaque formation, it seems
were determined by commercially available IRMA. reasonable to assume that similar mechanisms take placeResults. In stenosed hemodialysis fistulas, a pronounced inti-
during atherogenesis in hemodialysis patients. In uremicmal thickening with deposition of ECM was observed with
light and electron microscopy. Infiltrating cells were seen in patients undergoing hemodialysis, the risk for cardiovas-
stenosed vessels, mostly in areas of intimal hyperplasia and in cular complications is markedly elevated due to a num-
the media. TGF-1, LTBP-1 and IGF-I expression were mostly ber of reasons, including the presence of diabetes melli-localized in the neointimal and medial layers, and were signifi-
tus, hypertension, dyslipidemia or an elevated calcium-cantly higher than in the control groups. A positive correlation
between the presence of inflammatory cells and the staining phosphate product [8]. The latter is essentially involved
intensity for TGF-1, LTBP-1 and IGF-I was found in all in vascular calcifications that are often seen in these
vessels analyzed. patients [9]. Therefore, the stenotic AV fistula can beConclusion. Neointimal thickening of primary arteriove-
regarded as a model for accelerated atherogenesis.nous fistulas represents a local inflammatory process and ap-
Transforming growth factor- is a family of regulatorypears to be associated with increased protein expression of
TGF-1 and IGF-I. While local IGF-I is likely to stimulate proteins that are involved in mediating growth and dif-
smooth muscle cell proliferation in this setting, TGF-1 may ferentiation of many cell types [10]. TGF-s exhibit theirbe an important trigger of ECM production and deposition.
effects by binding to cell-surface receptors [11]. Three
distinct receptors (types I–III) have been identified in a
variety of cells including vascular smooth muscle cellsIn hemodialysis patients, the most frequent cause of
(VSMC). TGF-s influence atherogenesis via differenthospitalization is vascular access dysfunction often re-
mechanisms. TGF-s can act as potent inducers of matrix
biosynthesis [12–14] and show immunosuppressive andKey words: primary arteriovenous fistula, transforming growth factor-
anti-inflammatory effects [15, 16]. In vivo, TGF-s en-1, insulin-like growth factor-I, intimal hyperplasia, uremic vasculopa-
thy, atherogenesis, extracellular matrix. hance intimal thickening, an effect that could experimen-
tally be provoked by overexpression or administrationReceived for publication November 6, 2000
of TGF-1 [17, 18] or suppressed by using a neutralizingand in revised form July 13, 2001
Accepted for publication October 1, 2001 antiserum against TGF-1 [19]. TGF-1 is synthesized
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the mature form by proteolytic cleavage [10]. TGF-1 lesions in the venous outflow tract of hemodialysis fistu-
lae. However, non-stenotic, arterialized uremic veinsis secreted as an inactive high-molecular-weight mass
complex. The large latent complex of TGF-1 (LL-TGF- could not be obtained for ethical reasons.
The three groups were not different in age nor was1; 210 kD) from human platelets has been purified and
characterized [20]. This complex contains three compo- there a difference in the incidence of diabetes mellitus,
cerebral or peripheral ischemic disease. The distributionnents: the mature TGF-1 dimer non-covalently linked
to the N-terminal remnant of the TGF-1 precursor, that of cardiovascular risk factors was the same in the group
of uremic patients with stenotic veins and in the group ofis, 1-latency–associated peptide (1-LAP; 80 kD) and
the latent TGF-1 binding protein (LTBP; 125 to 160 uremic patients with normal veins. However, the distri-
bution of cardiovascular risk factors varied between ure-kD) [20, 21]. LTBP is a widely expressed multidomain
glycoprotein that ranges in size from 125 to 240 kD. Thus mic and non-renal patients. Uremic patients were hyper-
tensive to a higher percentage and showed secondaryfar, four different LTBPs have been identified: LTBP-1
to LTBP-4. Their homology to the fibrillins led to their hyperparathyroidism (sHPT) in about half of the cases.
Furthermore, the sex distribution was unequal in theinclusion into the so-called fibrillin superfamily [21].
LTBP-1 has been suggested to play a role as an extracel- group of patients with coronary artery disease (CAD),
which contained 13 males and only two females.lular fibrillar structure in the storage of TGF- as a large-
latent-TGF-–complex [21, 22]. Of the 15 patients with stenotic AV fistulas, seven
were female and eight were male. Their ages rangedInsulin-like growth factors (IGF) I and II are among
the most abundant and tightly regulated growth factors from 33 to 80 years (median 62 years), and the duration
of hemodialysis ranged from one to twelve years (medianpresent in human plasma. IGFs are mainly produced by
the liver but also can be produced locally by cells of the 3 years). Five patients suffered from chronic glomerulo-
nephritis, three had diabetic nephropathy, two showedcardiovascular system. Both IGF-I and IGF-II induce
several biological responses including cell proliferation, vascular nephropathy, two were unknown, one had lupus
nephritis, one reflux nephropathy and one Alport syn-inhibition of apoptosis and stimulation of cell migration,
which mainly are mediated through the type I IGF recep- drome. The ages of the 29 uremic patients (14 female/15
male) ranged from 28 to 82 years. Duration of dialysistor (IGF-IR). The biological actions of IGFs are modu-
lated by six different IGF-binding proteins (IGFBPs), ranged from 0 to 60 months with a median of 0 months.
Only nine of the uremic patients had been dialyzed atof which IGFBP-3 is the main circulatory IGF binding
protein [7]. Recent studies suggest that the IGFs stimu- all prior to AV fistula creation, thus explaining the me-
dian of 0 months. Distribution of renal disease was aslate atherogenesis via induction of VSMC proliferation,
stimulation of macrophage migration and induction of follows: six with chronic glomerulonephritis, nine with
diabetic nephropathy, one vascular nephropathy, fourcollagen synthesis [7]. A role for IGF-I in atherosclerosis
is emphasized by a study demonstrating serum IGF-I unknown, two analgesic nephropathies, one polycystic
kidney disease, and three with recurrent pyelonephritis.levels to be independently associated with coronary ar-
tery disease progression in young male survivors of myo- The ages of the 15 CAD patients ranged from 48 to 75
years (median 62 years). They had normal creatininecardial infarction [23].
The aim of our study was to investigate the involve- levels and no history of renal disease.
Tissue specimens were snap frozen in cold isopentanement of locally expressed TGF-1, LTBP-1 and IGF-I
in neointimal thickening of hemodialysis vascular access. cooled by liquid nitrogen and stored at 70C until pro-
cessed for immunohistochemistry. Samples for electronOur results suggest that both TGF-1 and IGF-I may be
involved in the pathogenesis of stenosis and subsequent microscopy were fixed in 2.5% glutaraldehyde, 0.1 mol/L
cacodylate buffer containing 1% saccharose at pH 7.4.thrombosis of primary arteriovenous fistulae.
Antibodies
METHODS
A polyclonal rabbit antiserum directed against the la-
Patients and tissue samples tency-associated peptide of TGF-1 (96-1) as well as an
antiserum against LTBP-1 (Ab-39) purified from humanFifteen occluded or severely narrowed vein segments
of primary AV fistulas just distal to the anastomosis were platelets were used as previously described [13]. Ab-39
was directed against a stretch of 12 endothelial growthobtained at the time of surgical revision. Twenty-nine
control vein segments were obtained from mostly pre- factor (EGF)–like repeats in the C-terminal half of
LTBP-1 and detected a single 200 kD band in immuno-dialytic patients at the time of their first primary shunt
operation. Fifteen control saphenous vein segments were blotting analysis of human fibroblast extracellular matrix
(ECM). To demonstrate the presence of IGF-I, a com-obtained from non-renal patients undergoing aortocoro-
nary venous bypass operation. Vessels of venous origin mercially available antibody (clone sm1.2; Upstate Bio-
technology, Lake Placid, NY, USA) was used. For identi-were needed as controls to be compared with the stenotic
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fication of different cell types, cell markers were detected pylene-oxide/epon. They were then incubated over night
on macrophages (mAb against CD68; Immunotech, Mar- in 30% propylene-oxide/70% epon and the next day
seille, France), on T lymphocytes (mAb against CD3; embedded in epon. Epon was allowed to polymerize for
Immunotech) and on endothelium (mAb against von- 60 hours. Ultrathin sections (60 nm) were stained with
Willebrand factor; Dako, Hamburg, Germany). 2% uranyl acetate and 2% lead citrate and examined in
an EM10 Zeiss electron microscope.
Serum levels of TGF-1 and IGF-I
Statistical analysisSerum levels of TGF-1 were determined using a com-
mercially available enzyme-linked immunosorbent assay To compare the expression of peptides between the
(ELISA; Quantikine human TGF-1; DB100; R&D Sys- different vessels, statistical calculations were performed
tems, Wiesbaden, Germany) according to the manufac- on the semiquantitative immunostaining data using the
turer’s instructions. This assay has a sensitivity of 7 pg/mL SAS system applying Kruskal-Wallis test (chi square ap-
with a working range of 31.2 to 2000 pg/mL. The serum proximation), Wilcoxon 2-sample test (normal approxi-
samples were diluted by 1:30 and activated by transient mation) and Holm’s adjustment [25]. The nonparametric
acidification before measurement. Serum levels of free Spearman correlational analysis between rank-ordered
IGF-I were determined by IRMA (active IGF-I-IRMA; raw numbers was used to assess the correlational pattern
DSL-9400; Diagnostic Systems Laboratories, Webster, between the presence of various cell types and the pres-
TX, USA) as previously described [24]. The assay has a ence of TGF-1, LTBP-1 or IGF-I expression. To com-
sensitivity of 0.03 ng/mL with a working range of 0.15 pare peptide serum levels, we again applied the Kruskal-
to 20.0 ng/mL. Wallis test with a subsequent Wilcoxon 2-sample test.
Results were considered significant with a probabilityImmunohistochemistry
level of P  0.05 and are given as median [1st quartile;
The vascular segments were cryosectioned into 5 m 3rd quartile].
slices, fixed in ice-cold 100% acetone for 10 minutes,
air-dried and stored at 70C. Endogenous peroxidase
RESULTSactivity was quenched by 0.3% hydrogen peroxide in
cold methanol. An avidin-biotin blocking kit (Vector Failing AV shunts show pronounced
Laboratories, Burlingame, CA, USA) was used to pre- intimal thickening
vent non-specific reactions between endogenous biotin
In most shunts requiring surgical revision, a pro-and the detection system. To prevent unspecific binding
nounced intimal thickening was observed adjacent toof the primary antibodies, the sections were blocked with
the site of anastomosis. The intimal hyperplasia largelyphosphate-buffered saline (PBS) containing 10% normal
consisted of smooth muscle cells and extracellular matrixgoat serum (for anti-TGF-1, anti-LTBP and anti-von-
(Fig. 1A). In comparison to VSMC in the media (Fig. 1B),Willebrand factor) or 10% normal horse serum (for anti-
the orientation of the neointimal VSMC appeared ratherCD3 and anti-CD68). The sections were incubated with
disorganized (Fig. 1A).the primary antibody over-night at4C in a humidified
chamber. The Vectastain avidin-biotin-peroxidase com- Local inflammation in stenotic hemodialysis fistulae
plex kit (Vector Laboratories) was used for detection
Macrophages and infiltrating lymphocytes were de-of the immunoreaction. It contained either biotinylated
tectable near the base of the neointima and in its luminalgoat anti-rabbit or horse anti-mouse antibodies and an
aspect of stenotic vessels just below the endothelium.avidin-biotin peroxidase complex. The immunocomplexes
Moreover, CD68 positive macrophages and infiltratingwere visualized by aminoethylcarbazole and 0.3% hydro-
CD3 positive lymphocytes were found in the medial layergen peroxide. The sections were counterstained with he-
(Fig. 2). A thrombus totally occluded the lumen of fourmalaun.
stenotic fistulae. These thrombi showed no layering sug-The stained sections were evaluated by two of the
gestive of episodic thrombus formation. At the interfaceauthors independently (SS, JW). The viewers were
between thrombus and endothelium, infiltrating cellsblinded with regard to the origin of the vascular material
could be seen in all samples. More macrophages andwhen performing the scoring. Photomicrographs were
lymphocytes were seen in the stenosed vessels when com-taken with a light microscope (Axiophot; Zeiss, Ober-
pared to both types of control vessels (P  0.05). Thekochen, Germany). A semiquantitative scheme was ap-
non-stenosed uremic and non-uremic vessels did not dif-plied to evaluate tissue sections referring to the intensity
fer for the presence of macrophages and lymphocytes.of the immunostaining (Table 2).
Both cell types could be seen in small amounts in the
Electron microscopy intimal and—slightly more abundantly—in the medial
layer. By applying the non-parametric Spearman correla-Fixed specimens were dehydrated through a graded
series of ethanol and processed through a series of pro- tion analysis, there was a positive correlation between
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Fig. 1. The intimal hyperplasia of failing arte-
riovenous (AV) shunts largely consisted of
vascular smooth muscle cells (VSMC). When
compared to the medial VSMC (B), the orien-
tation of the neointimal VSMC (A) was dis-
organized with no specific longitudinal or
circumferential preference, and wide intercel-
lular spaces filled with extracellular matrix
(ECM) could be seen. Bar represents 5 m,
original magnification 5000.
the presence of macrophages/lymphocytes and the stain- man saphenous veins differed in their TGF-1 expres-
ing intensity of TGF-1, LTBP-1 and IGF-I, which was sion only in the abluminal part of the intima where
true for all vessels analyzed (Table 1). TGF-1 was found in higher amounts in the non-ste-
nosed but uremic vessels. The non-parametric Spearman
Expression of TGF-1 in stenotic hemodialysis correlational analysis revealed a positive correlation be-
fistula and in vein segments from uremic tween the neointimal cell number and the expression of
and non-uremic controls TGF-1. The correlation coefficient for TGF-1 staining
intensity versus cell number was 0.47 for the luminalTransforming growth factor-1 expression was found
aspect (P 0.05) and 0.58 for the abluminal aspect (Pto be significantly higher in the luminal and abluminal
0.05) in the (neo)intima for all vessels. Based on the(neo)intima, in the medial layer and in the vasa vasorum
spatial distribution of the staining pattern, the majorityof the stenosed vessels as compared to non-stenosed
of TGF-1 expressing cells can be regarded as vascularuremic vessels and to non-uremic control vessels (Fig. 3
and Table 2). The non-stenosed uremic vessels and hu- smooth muscle cells.
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Fig. 2. Infiltrating leukocytes in stenosed he-
modialysis fistulae. CD68 macrophages (A)
and CD3 T lymphocytes (B) can be seen
in high numbers in the neointima and in the
media. In both types of control vessels very
few macrophages/lymphocytes could be de-
tected. Bar represents 100m, original magni-
fication 40. Arrowhead points to internal
elastic membrane.
Table 1. Correlation between the presence of CD3 lymphocytes and CD68 macrophages and the expression of TGF-1,
LTBP-1 and IGF-I for all vessels applying the Spearman correlation analysis
Correlation coefficient between Correlation coefficient between Correlation coefficient between
TGF-1 staining intensity and LTBP-1 staining intensity and IGF-I staining intensity and
Vessel layer CD3 cells CD68 cells CD3 cells CD68 cells CD3 cells CD68 cells
Endothelium 0.25 — 0.08 — 0.08 —
Luminal intima 0.39 0.25 0.38 0.43 0.48 0.49
Abluminal intima 0.57 0.51 0.38 0.39 0.51 0.64
Media 0.42 0.29 0.32 0.32 0.35 0.38
Adventitia 0.04 0.05 0.03 0.15 0.04 0.09
Ranges are: 0.0–0.3, no correlation; 0.3–0.5, moderate correlation; 0.5, strong correlation. Abbreviations are: TGF-1, transforming growth factor-1; LTBP-1,
latent TGF- binding protein-1; IGF-I, insulin-like growth factor-I.
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Fig. 3. Expression of transforming growth factor 1 (TGF-1), latent TGF-1 binding protein-1 (LTBP-1) and insulin-like growth factor-I (IGF-I)
in stenosed and control vein segments. Immunohistochemical staining recognizing the latent form of TGF-1 (A–C), LTBP-1 (D–F ) and IGF-I (G–I)
was performed. The intima is separated from the medial layer by the internal elastic membrane (arrowhead). TGF-1 and IGF-I immunostaining are
located intracellularly. TGF-1 and IGF-I expression are found to be significantly higher in the neointimal and medial layer of the stenosed vessels
(A, G) when compared to non-stenosed uremic vessels (B, H) and to human saphenous veins of non-uremic patients (C, I). All LTBP-1
immunostaining is located extracellularly. Paralleling TGF-1 staining, LTBP-1 expression is found to be significantly higher in the neointimal
and medial layer of the stenosed vessels (D) compared to non-stenosed uremic vessels (E). Human saphenous veins (F), however, often showed
a similar LTBP-1 expression as the stenosed fistulae in the endothelium and the neointima. Bar represents 100 m, original magnification 40.
Expression of LTBP-1 in stenotic hemodialysis number and the expression of LTBP-1. The correlation
fistula and in vein segments from uremic coefficient was found to be 0.58 for the luminal aspect
and non-uremic controls (P  0.05) and 0.53 for the abluminal aspect (P  0.05).
Latent TGF-1 binding protein-1 expression was found
Expression of IGF-I in stenotic hemodialysisto be significantly higher in the endothelium, in the lumi-
fistula and in vein segments from uremicnal (neo)intima and in the medial layer of the stenosed
and non-uremic controlsvessels compared to non-stenosed uremic vessels (Fig. 3
Insulin-like growth factor-I expression was found to beand Table 2). When compared to non-uremic vessels,
significantly higher in the endothelium, the (neo)intima,the stenosed fistulas showed higher LTBP-1 expression
and in the medial layer of the stenosed vessels comparedonly in the medial layer but comparable LTBP-1 expres-
to both types of control vessels (Fig. 3 and Table 2). Thesion in the endothelium and the intima (Fig. 3F and
non-stenosed uremic and the non-uremic control vesselsTable 2). The non-stenosed uremic vessels and the non-
did not differ in their IGF-I expression. As for TGF-1,uremic vessels differed in their LTBP-1 expression in the
a positive correlation between the neointimal cell numberendothelium, luminal part of the intima and the vasa
and the expression of IGF-I was detected. The correlationvasorum, where LTBP-1 was found in higher amounts
coefficient measured 0.53 for the luminal aspect (P in the non-uremic vessels. As for TGF-1, likewise there
was a positive correlation between the neointimal cell 0.05) and 0.49 for the abluminal aspect (P  0.05).
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Table 2. Immunostaining of stenosed hemodialysis fistulae and uremic and non-uremic control vessels for TGF-1, LTBP-1 and IGF-I.
(Neo)intima
Endothelium Luminal Abluminal Media Adventitia Vasa vasorum
Stenosed fistulae
Anti-TGF-1 0.5 2.0 1.5 3.0 0 3.0
[0; 1.5] [1.25; 2.25]ab [0.75; 2.0]ab [2.75; 3.0]ab [0; 0.25] [2.75; 3.0]ab
Anti-LTBP-1 2.5 2.5 1.0 2.0 0.75 1.5
[2.0; 3.0]a [1.5; 2.5]a [0.5; 2.0] [2.0; 2.38]ab [0.13; 1.0] [1.5; 2.9]
Anti-IGF-I 2.5 2.0 2.0 3.0 0 2.0
[1.375; 3.0]ab [2.0; 2.75]ab [1.5; 2.5]ab [2.5; 3.0]ab [0; 0.5] [1.0; 2.0]
Uremic control vessels
Anti-TGF-1 0 1.0 0 2.0 0 2.0
[0; 1.0] [0; 1.5] [0; 0.13] [1.0; 3.0] [0; 0.5] [1.75; 3.0]
Anti-LTBP-1 2.0 1.5 0.5 1.5 1.0 1.5
[1.5; 2.5] [1.0; 2.0] [0; 1.0] [1.0; 2.0] [0.5; 1.0] [1.0; 1.5]
Anti-IGF-I 1.0 0 0 1.5 0 1.0
[0.875; 1.5] [0; 1.0] [0; 0.125] [1.0; 2.125] [0; 0.875] [1.0; 1.75]
Human saphenous veins
Anti-TGF-1 0.5 1.0 0.5 2.0 0.5 2.5
[0.13; 1.0] [0.5; 1.5] [0; 0.75]a [1.5; 2.25] [0; 0.5] [1.5; 2.5]
Anti-LTBP-1 2.50 2.0 0.5 1.5 1.0 2.0
[2.25; 3.0]a [1.25; 2.25]a [0.5; 0.75] [1.0; 1.5] [1.0; 1.0]c [2.0; 2.5]
Anti-IGF-I 0.25 0 0 2.0 0 1.0
[0; 1.625] [0; 1.0] [0; 0.5] [1.0; 2.5] [0; 0.625] [0.5; 2.0]
The specimens were independently viewed by two of the authors (S.S., J.W.). The relative staining intensity of the indicated vessel area was evaluated applying
a semiquantitative scheme: 0 	 no staining, 1 	 weak staining, 2 	 moderate staining, 3 	 strong staining. The staining intensity is given as median [1st quartile; 3rd
quartile].
a P  0.05 vs. uremic control vessels
b P  0.05 vs. uremic control vessels and human saphenous veins
c P  0.05 vs. stenosed fistula
Serum levels of TGF-1 and IGF-I we have found TGF-1 and IGF-I immunoreactivity in
the neointimal and in the medial layers as well as in theThere was no statistically significant difference be-
vasa vasorum of the stenosed vessels. In contrast, non-tween the three groups of patients concerning serum
stenosed vessels from both uremic and non-uremic pa-levels of TGF-1 or IGF-I. No correlation could be ob-
tients expressed much lower levels of TGF-1 and IGF-Iserved between serum levels and the intensity of the local
protein. The up-regulation of TGF-1 in AV fistulas wasgrowth factor expression. TGF-1 levels were similar in
confirmed recently by others [26]. However, that reportall groups and measured 32 ng/mL (22.9; 45.7) [median
focused on erythropoietin as a cytokine that may trigger(1st quartile; 3rd quartile)] in patients with stenosed fis-
the increase of TGF-1 expression. TGF-1 and IGF-Itulae, 21 ng/mL (15.6; 29.8) in the uremic controls and 30
seem to be produced locally by medial and neointimalng/mL (25.2; 35.4) in non-uremic patients with coronary
smooth muscle cells as well as by macrophages and lym-artery disease. Likewise, IGF-I serum levels did not vary
phocytes within the stenotic lesion of AV fistulas in he-significantly with 0.26 ng/mL (0.24; 0.28) for patients
modialysis patients. We were not able to find a correla-with stenosed fistulas, 0.33 ng/mL (0.21; 0.46) for uremic
tion between the local expression of TGF-1 and IGF-Icontrols and 0.36 ng/mL (0.33; 0.48) for non-uremic con-
and their respective serum levels.trol patients with CAD.
The location of TGF-1, however, is not necessarily
the site of action of TGF-1, as this growth factor has
DISCUSSION to go through a multistep procedure of activation and
has to leave the cytoplasm of the producer cell. AfterThe results show a significantly increased expression
secretion, the large latent form of TGF-1 associatesof TGF-1, LTBP-1 and IGF-I in stenotic AV fistulas of
with the extracellular matrix via LTBP-1, and the releasehemodialysis patients when compared to non-stenosed
of the small latent TGF-1 complex from the ECM is avessels of uremic and non-uremic patients. Expression of
consequence of the proteolytic cleavage of LTBP-1. Ourthese growth factors strongly correlates with neointima
current understanding proposes a model of activation information and is strongly associated with a local inflam-
which latent TGF-1 is released from the extracellularmatory process involving lymphocytes and macrophages.
matrix by proteases cleaving LTBP-1, subsequently lo-Transforming growth factor-1 and IGF-I have been
shown to be involved in the pathogenesis of atherosclero- calized to cell surfaces by either latency-associated pep-
tide or LTBP-1, and activated by cell-associated plasminsis [6]. In failing AV fistulas of hemodialysis patients,
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[27]. An accumulation of LTBP-1 over time due to a respond to both growth factors [35, 37]. The expression
of TGF-1 and TGF- type II receptors within the athero-longer half-life of LTBP-1 versus TGF-1 has been sug-
sclerotic lesion is strongly associated with the presence ofgested earlier [6, 27], and, therefore, we used LTBP-1
inflammatory cells [35]. For the type-I IGF-receptor,as a marker for TGF-1 production because it should
it was shown that its presence on macrophages enablesbe more sensitive than the presence of latent TGF-1
IGF-I to increase macrophage concentrations at sites ofitself.
injury [37]. IGF-I secreted within the lesion can act asInsulin-like growth factors (IGFs) and their binding
a monocyte chemotactic agent. Both TGF-1 and IGF-Iproteins have been characterized as key regulators of
are stored in platelets and can be released by plateletsgrowth and differentiation in most cell types and tissues
at the site of vessel injury. Our study found macrophagesincluding the cardiovascular system [7]. In the present
and infiltrating lymphocytes in the neointima and mediastudy, a significant up-regulation of IGF-I expression
of stenotic hemodialysis fistulae. There was also a posi-was found in the endothelium, the neointima and in the
tive correlation between the presence of macrophages/medial layer of the stenosed vessels. These changes may
lymphocytes and the expression of TGF-1, LTBP-1 andcontribute to the underlying pathogenesis because previ-
IGF-I, which was true for all vessels analyzed. We there-ous studies revealed that IGF-I preferentially increases
fore suggest a major role of macrophages and T lympho-heparan sulfate-containing proteoglycans [28] and stimu-
cytes in contributing to the production of TGF-1 andlates endothelial cell-monocyte adhesion by means of
IGF-I and possibly in contributing to the remodeling ofincreasing the expression of ICAM-1 and VCAM-1 [29].
the stenosed vessels. Remodeling represents a processOur present study used saphenous vein segments from
that results in excessive neointimal matrix depositionpatients undergoing aortocoronary bypass grafting as
and luminal narrowing [38].control vessels. We chose vein segments as controls be-
Increased production and deposition of ECM proteinscause the stenosis of a hemodialysis fistula usually devel-
is a major feature during the remodeling of atheroscle-ops in the venous part of the fistula just downstream
rotic tissue [38]. TGF-1 is well known to stimulate theto the anastomosis. Notably, we observed that intimal
production of extracellular matrix and to induce fibrosishyperplasia was present in many saphenous veins at the
[13, 14, 18, 19]. Likewise, though IGF-I is usually seentime of harvesting. So far, only few morphological studies
as a proliferative and anti-apoptotic cytokine, it alsohave shown the presence of pre-existing pathological
has been demonstrated to induce ECM proteins and tochanges in the human saphenous vein [30–32]. Very few
interact with TGF-1. A concomitant up-regulation ofreports have addressed the idea that the severity of pre-
IGF-I and collagen I mRNA in VSMCs and macro-existing changes of venous grafts may be a predictor for
phages could be demonstrated in human atherosclerotic
the development of vein graft stenosis [31, 32]. When tissue [39]. Induction of TGF-1 by IGF-I has been de-
compared to the uremic control vessels of venous origin, scribed as a possible mechanism for the up-regulation
an increased staining intensity for LTBP-1 can be seen of ECM [40].
in the endothelium, in the luminal aspect of the intima In conclusion, neointimal thickening of primary arte-
and in the vasa vasorum of the saphenous vein segments. riovenous fistulae appears to be a local inflammatory
The saphenous veins even show an endothelial and neo- process up-regulating both TGF-1 and IGF-I. IGF-I
intimal LTBP-1 expression that is comparable to that of acts pro-atherogenic predominantly by inducing VSMC
the stenosed hemodialysis fistulas. A pre-existing intimal proliferation and TGF-1 by stimulating the production
hyperplasia of saphenous veins (from patients with coro- of ECM proteins. We hypothesize that local inflamma-
nary artery disease) as well as the observed increased tion and possibly IGF-I–induced VSCM proliferation
growth factor expression prior to explantation seems to are early mechanisms in the development of stenoses in
be an indicator for the systemic nature of atherosclerosis. hemodialysis fistula. This may trigger an inadequately high
Additionally, this finding opposes the view that increased expression of TGF-1, which—besides its anti-inflam-
growth factor expression in stenotic hemodialysis fistulas matory and anti-proliferative activities—leads to exces-
is simply the result of arterialization of the vein. sive and irreversible deposition of ECM. For the design
Atherosclerosis is regarded as an inflammatory disease of future therapeutic strategies to prevent pro-athero-
[33]. Endothelial injury and dysfunction as elicited by a genic processes in AV fistulas and to improve shunt pat-
number of known risk factors leads to the adhesion of ency, it should be a final goal to therapeutically block the
platelets and leukocytes and to the formation of cyto- signal for matrix production while leaving other activities
kines and growth factors such as TGF-, platelet-derived such as the anti-inflammatory action of TGF-1 un-
growth factor (PDGF) and IGF-I. The inflammatory re- touched.
sponse is mediated by macrophages, T lymphocytes [34]
and by interferon-
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